Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03316131 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03316131 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 36 participants.
The verdict
NCT03316131, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit
Interventions
- DRUG Dapagliflozin
- DRUG Febuxostat
- DRUG Verinurad
- OTHER Dapagliflozin matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2018-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03316131
The ClinicalTrials.gov registry entry for NCT03316131 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dapagliflozin is the first listed.
NCT03316131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03316131 about?
NCT03316131 is a clinical study titled "A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA". This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit
What is the current status of trial NCT03316131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-10-25. Estimated completion is 2018-07-19.
What interventions are being tested in trial NCT03316131?
The interventions under investigation include: Dapagliflozin (DRUG), Febuxostat (DRUG), Verinurad (DRUG), Dapagliflozin matched placebo (OTHER).
Who is sponsoring clinical trial NCT03316131?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.